Physician profile
Joseph J Thimons
NPI 1851371454
$340,171.34
in general payments reported to CMS, 2019-2025
35 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $66K · 2021: $32K · 2022: $22K · 2023: $46K · 2024: $52K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $80K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $13K · Consulting Fee: $12K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $79,550.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,900.00 |
| Travel and Lodging | $12,571.15 |
| Consulting Fee | $12,285.00 |
| Food and Beverage | $11,922.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $91,922.46 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $62,834.02 | 2019-2025 | Cequa |
| Reichert, INC. | $50,050.00 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32,901.24 | 2019-2021 | |
| Allergan, INC. | $23,353.62 | 2019-2022 | |
| Lkc Technologies, INC. | $17,550.01 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $14,949.02 | 2019-2023 | |
| Shire North American Group INC | $11,431.17 | 2019 | |
| Oyster Point Pharma, INC. | $7,436.17 | 2022-2025 | Ryzumvi, Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $6,093.15 | 2019-2023 | Tearcare System |
| Glaukos Corporation | $5,921.37 | 2019-2025 | Radius Xr, Radius, Idose |
| Aerie Pharmaceuticals, INC. | $4,159.29 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $2,557.42 | 2019-2022 | |
| Alcon Vision LLC | $1,957.68 | 2019-2025 | Tryptyr, Rocklatan, Eysuvis |
| Thea Pharma INC. | $1,506.24 | 2023-2025 | Iyuzeh |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Derma Sciences, INC. | $1,350.00 | 2019 | |
| Carl Zeiss Meditec, INC. | $895.47 | 2019-2024 | Visumax, Atlas 500, Mel 90 |
| Tarsus Pharmaceuticals, INC. | $601.48 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $533.51 | 2019-2020 | |
| Abbvie INC. | $476.52 | 2022-2025 | |
| Biotissue Holdings INC. | $458.83 | 2021-2025 | |
| Rxsight INC | $383.02 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Dompe US, INC. | $153.25 | 2019-2025 | Oxervate |
| Ars Pharmaceuticals Operations, INC. | $124.96 | 2025 | Neffy |
| Maculogix, INC. | $116.15 | 2019 | |
| Coopervision INC. | $111.91 | 2019 | |
| Quidel Corporation | $94.23 | 2019-2020 | |
| Optovue, INC. | $71.40 | 2019 | |
| Horizon Therapeutics Plc | $58.67 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $46.20 | 2024-2025 | Dextenza |
| Tearlab Corp | $22.94 | 2024 | Scoutpro Osmolarity System |
| Ani Pharmaceuticals, INC. | $18.79 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $16.94 | 2019 | |
| Harrow Eye, LLC | $14.21 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Thimons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.